TechCrunch→ original

SandboxAQ launched its drug discovery models in Claude

SandboxAQ integrated its drug discovery models into Claude. The startup believes the main obstacle is not the quality of AI, but access to it. Biochemists will

SandboxAQ launched its drug discovery models in Claude
Source: TechCrunch. Collage: Hamidun News.
◐ Listen to article

SandboxAQ has embedded its drug discovery models in Claude, making cutting-edge biocomputational tools accessible to researchers without specialized training in computer science.

Accessibility over quality

While competitors like Chai Discovery and Isomorphic Labs chase improvements to the models themselves, SandboxAQ is betting on something different: the main barrier to AI adoption in drug development is not a lack of quality, but the absence of a simple interface for the target audience. The models are already powerful enough. But they are owned primarily by large companies with their own teams of data scientists. Meanwhile, most biochemists and molecular biologists have never written code. The integration with Claude closes precisely this gap.

How it works

A researcher opens Claude and asks a question in plain language: "Give recommendations for optimizing this compound," "Predict the activity of this molecule in this context," "What analogs exist in the literature." SandboxAQ models process the request, analyze molecular structures, and deliver results. No code, no format parsing. The biologist remains in a familiar environment but gains access to tools that previously required computer science expertise.

Competition in AI for life sciences

Several players are already active in the drug discovery tools market:

  • Chai Discovery — creates models for molecular design and property prediction
  • Isomorphic Labs (DeepMind subsidiary) — focuses on predicting 3D protein structures
  • SandboxAQ — embeds tools in popular platforms like Claude

Each has chosen its own path, but all agree: AI dramatically reduces the time and cost of molecular development. What once took years now takes months.

What this means

This integration shows that AI for life sciences is moving out of laboratories into mainstream products. Embedding capabilities into familiar interfaces is sometimes more effective than improving the algorithms themselves. This could accelerate drug development in small companies and universities that lack their own machine learning departments.

ZK
Hamidun News
AI news without noise. Daily editorial selection from 400+ sources. A product by Zhemal Khamidun, Head of AI at Alpina Digital.
What do you think?
Loading comments…